Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
261 results about "Blood uric acid" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Lactobacillus casei strain and probiotic composition for lowering blood uric acid and application thereof
The invention provides a lactobacillus casei strain and a probiotic composition for lowering blood uric acid and application thereof, and belongs to the technical field of food medicines. The lactobacillus casei strain ZM15 for lowering the blood uric acid has the collection number of CGMCC No.13980. The lactobacillus casei strain ZM15 has the rates of degrading adenylic acid, guanylic acid, adenosine and guanosine as high as 100%; a degraded product does not contain uric acid and allantoin; in addition, the degraded product has a low purine base proportion of only 0.10%, so that the product can be prevented from being further decomposed into the uric acid, and the human blood uric acid content can be effectively reduced. The probiotic composition provided by the invention is obtained by compounding four strains of ZM15, ZM18, ZM122 and ZM05; through mutual coordination of the four strains, the blood uric acid lowering effect of the probiotic composition is significantly better than that during independent application of ZM15, ZM18, ZM122 and ZM05 strains, so that the blood uric acid lowering effect can be further improved.
Owner:JIAXING INNOCUL PROBIOTICS CO LTD
Compound chicory series product and effect of adjusting blood sugar, blood fat and blood uric acid
InactiveCN101791383ASimple compositionLow costMetabolism disorderSkeletal disorderBiotechnologyRed yeast rice
The invention discloses a compound chicory series product and a preparation method thereof. The series product is prepared from main component chicory and one or more yam rhizome, semen coicis, rhizoma smilacis glabrae, Siegesbeckia herb, longhairy antenoron herb, cutch, mulberry leaf, kudzu-vine root, barbary wolfberry fruit, poria cocos, corn stigma, guava leaf, red yeast rice, cassia seed, hawthorn, lotus leaf, aloe and nano selenium according to different applications of the product. The product has the main characteristics of synchronous adjusting effect on endocrine disorder and obvious effects on adjustment of blood uric acid, blood sugar and blood fat and immunity reinforcement, wide adaptive crowd and positive economic and social significance and is easy to realize industrialized large production.
Owner:崔晓廷
Application of sunflower disc hydrolysis compound powder in preparing of medicine for curing or relieving high uric acid gout
Application of sunflower disc hydrolysis compound powder in preparing of food, medicine or food and medicine composition for preventing, curing or relieving blood uric acid rising-related diseases belongs to the technical field of biological medicine. According to the sunflower disc hydrolysis compound powder, by a method of hydrolyzing a soak solution of a sunflower disc with enzyme, on the basis of not damaging original components of the sunflower disc as much as possible, plant large molecules in the sunflower disc are hydrolyzed into micro-molecule polypeptide. It is found for the first time in research that the sunflower disc hydrolysis compound powder has an action of preventing rising of blood uric acid in animals, and also has a potential action of reducing high uric acid formed in blood. Therefore, the sunflower disc hydrolysis compound powder should be applied in preparing of food, medicine or food and medicine composition for relieving or curing gout.
Owner:JILIN PROVINCE TEYIFOOD BIOTECH CO LTD
Lactic acid bacterium having effect of lowering blood uric acid level
The present invention provides lactic acid bacteria which are suitable for use for dietary products and pharmaceuticals, and which can suppress the increase of blood uric acid level.Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2922, were found.
Owner:MEIJI CO LTD
Lactobacillus plantarum UA-416 strain and application thereof
ActiveCN108048368ALower serum uric acidInhibits oxidase activityBacteriaSkeletal disorderCreatinine riseTherapeutic effect
The invention discloses a lactobacillus plantarum UA-416 strain and application thereof, and belongs to the field of functional food microbes. Blanks of lactobacillus plantarum in the effects of lowering uric acid and resisting gout are filled up. According to the lactobacillus plantarum (Lactobacillus plantarum) UA-416 strain provided by the invention, the bacterial strain is already collected inthe China Center for Type Culture Collection (CCTCC) on July 25, 2017; the collection number is CCTCC NO: M2017419. The lactobacillus plantarum UA-416 strain provided by the invention can be used foreffectively lowering the level of blood uric acid, is used for improving the levels of urea nitrogen and creatinine and inhibiting the activity of xanthine oxidase in serum, and has prevention and treatment effects on uricemia or the gout.
Owner:JILIN MINGZHIYUAN BIOTECH
Ache relieving mixture for treating urarthritis
InactiveCN101185730ALow costSimple processing technologySkeletal disorderLeech/worm material medical ingredientsSide effectMyrrh
The invention relates to a pain-relieving mixture for the treatment of gouty arthritis, which pertains to the field of pharmaceutical formulations, the technology is characterized in that: the parts by weight of the raw materials are: 6 to 10 percent amur corktree bark, 12 to 16 percent sevenlobed yam rhizome, 4 to 6 percent rhubarb, 8 to 12 percent Japanese honeysuckle stem, 6 to 9 percent Indian iphigenia bulb, 12 to 16 percent spreading hedyotis herb, 6 to 10 percent glabrous greenbrier rhizome, 4 to 6 percent frankincense, 4 to 6 percent myrrh, 6 to 10 percent clematis root, 6 to 10 percent largeleaf gentian root and 6 to 9 percent earthworm, and the sum of the percentages of the components of the raw materials is equal to 100 percent. The invention can effectively alleviate the symptoms of gouty arthritis, prevent and treat the repeated attacks of gouty arthritis, lower blood uric acid, have no toxicity or side effects and have definite efficacy.
Owner:申海莉
Method of producing whole blood detecting electrode strip and reaction film formulation and the related products
ActiveUS20040081752A1Immobilised enzymesBioreactor/fermenter combinationsPhysicsWater soluble polymers
The present invention relates to a method of producing a non-enzymatic detecting electrode strip for use on whole blood, including: a. coating a conducting film on one side of an electrically insulating substrate to form an electrode system with an isolated and disconnected anode and cathode; b. coating an electrically insulating film on a part of the anode and cathode of the electrode system, wherein one end of the anode uncovered with the conducting film forms at least a reference electrode and the other end forms an anode connector, one end of the cathode uncovered with the conducting film forms at least a working electrode and the other end forms a cathode connector, and an exposed part of the electrode system not covered with the insulating film forms an electrochemical reaction zone for forming a reaction layer; and c. adding dropwise a reaction film formulation onto the electrochemical reaction zone described in step (b), and drying it to form the reaction layer, wherein the formulation comprises an electron mediator, a water-soluble polymer carrier and a water solution to aid even dispersion. The present invention further relates to a reaction film formulation used in the production of a non-enzymatic whole blood uric acid detecting electrode strip, and a whole blood detecting electrode strip, a whole blood biosensor system using the whole blood detecting electrode strip produced by the aforementioned method.
Owner:APEX BIOTECH
L-aspartic acid for the treatment of assorted health problems
A method of treating or preventing one's health problem that are associated with one's cells having a poor metabolic capability to process fat includes ingesting a therapeutically effective dosage of an anaplerotic precursor. Examples of such health problems include obesity and the related health conditions that are aggravated by obesity, diabetes, hypertension, atherosclerosis, migraines and headaches, menstrual cramps, cholesterol excesses, multiple sclerosis and Alzheimer's disease, anemia, high blood uric acid levels, ketosis, tobacco and other drug addictions, and digestive problems. In a preferred embodiment, this method includes the daily ingestion of L-aspartic acid, or a pharmaceutically acceptable analog thereof, at the rate of 10-14 g / day and restricting from one's diet the intake of starchy foods.
Owner:INST DEL METABOLISMO CELULAR
Ring-fused compound
InactiveUS20140005221A1Promote uric acid excretionLower blood uric acid levelsBiocideOrganic chemistryURAT1 InhibitorsChemical compound
The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below.[in the formula,R1 is -Q1-A1 and the like; is a double bond or a single bond; when is a double bond, W1 is a nitrogen atom or a group represented by the general formula: ═C(Ra)—, and W2 is a nitrogen atom or a group represented by the general formula: ═C(Rb)—; when is a single bond, W1 is a group represented by the general formula: —C(Raa)(Rab)— or a group represented by the general formula: —(C═O)—, and W2 is a group represented by the general formula: —C(Rba)(Rbb)—, a group represented by the general formula: —(C═O)— or a group represented by the general formula: —N(Rbc)—; W3, W4 and W5 are each independently a nitrogen atom or a methine group and the like that may have a substituent; X is a single bond, an oxygen atom and the like; Y is a single bond or (CRYiRYi′)n; and Z is a hydroxyl group or COOR2 and the like.
Owner:SATO PHARMA
Test paper for detecting uric acid content range in urine
InactiveCN101025415APlay a monitoring roleLow detection costAnalysis using chemical indicatorsMaterial analysis by observing effect on chemical indicatorPaper basedColor reaction
The invention relates to a test paper strip of using color reaction to detect the concentration of uric acid in urine. It includes test paper base material, its feature is that: enzyme color developing reagent adheres to test paper base material. The beneficial effect of this invention is that, the detector can detect the concentration of uric acid in urine in own home, so as to preliminary reach the range of uric acid content in the urine, thus it is certain guiding significance for the blood uric acid content.
Owner:SHUNDE POLYTECHNIC
Method for building animal model with hyperuricemia-combined diabetes
The invention discloses a method for building an animal model with hyperuricemia-combined diabetes. The method comprises the following steps: 1) feeding an target animal with fodder containing 10% (by mass) of yeast powder; subjecting the target animal to a lavage with a 4% (by mass) adenine water solution according to the following dosage of 100 milligram of adenine per day per kilogram of body weight until the blood uric acid level of the target animal starts falling; 2) halving the dosage of the adenine water solution in step 1), subjecting the target animal to a subcutaneous injection with an oteracil potassium emulsion twice a day according to the following dosage of 100 milligram of oteracil potassium emulsion per day per kilogram of body weight until the target animal shows clinical symptoms of diabetes, and then obtaining the animal model with the hyperuricemia-combined diabetes. The method builds the animal model with the hyperuricemia-combined diabetes for the first time, the animal model has typical disease symptoms, the quantity index has statistical significance, and studies such as glucose clamp test and immunohistochemistry also prove that the modeling is successful. Therefore, the method for building the animal model with the hyperuricemia-combined diabetes is a reliable and practical technique.
Owner:李长贵
Medicinal food formula and medicinal edible preparation for preventing and treating hyperuricemia and gout
InactiveCN102895320ANo side effectsSignificant effectPre-extraction tea treatmentSkeletal disorderFood additiveAcute toxicity testing
The invention belongs to the field of traditional Chinese medicines, relates to traditional Chinese medicines and health care preparations, and especially relates to a medicinal food formula and a medicinal edible preparation for preventing and treating hyperuricemia and gout. The medicinal edible preparation comprises traditional Chinese medicines or active ingredients of 10 to 80 parts of plantain seed and 10 to 80 parts of semen cuscutae. The medicinal edible preparation is prepared from extract of plantain seed and semen cuscutae, and auxiliary materials, and can be processed into tablets, pills, electuary, an oral liquid, a tea bag and a health-care food additive. An animal acute toxicity test and a sub-chronic toxicity test prove that the medicinal edible preparation is safe and has no toxic or side effect. A pharmacodynamic animal test proves that the medicinal edible preparation can obviously reduce blood uric acid and improve kidney uric acid crystallization and injuries. The medicinal edible preparation as a treatment drug or a health-care product can be used for patients suffering from hyperuricemia and gout, can obviously reduce a blood uric acid level and relieve gouty arthritis symptoms, and has good safety.
Owner:张清仲
Lactic acid bacteria having action of lowering blood uric acid level
ActiveUS20110014168A1Remarkable nucleoside-decomposing abilitySuppress increaseBiocideBacteriaLactic acid bacteriumUA - Uric acid
Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2959 and Lactobacillus oris OLL2779, were found.
Owner:MEIJI CO LTD
Chinese medicinal composition for reducing blood uric acid
The invention relates to a Chinese medicinal composition for reducing blood uric acid. The Chinese medicinal composition consists of active ingredient extracts prepared from glabrous greenbrier rhizome and oriental water plantain rhizome serving as raw materials and medicinal dressing, and can be prepared into various medicinally acceptable preparations and injection. The Chinese medicinal composition has the effects of removing dampness, releasing toxin and benefiting joints, and is mainly used for gouty arthritis and hyperuricemia.
Owner:戴永青 +2
Prepn and application in preparing medicine of Fraxinus general coumarin
The present invention provides a new application of Fraxinus general counmarin and aesculetin as the extractives of Chinese medicine material cortex Fraxini. The said two has obvious effects of stopping pain, resisting inflammation and reducing blood uric acid. They has obvious curative effect on acute and chronic gout and no obvious toxic side-effect. The present invention also provides a simple preparation process of Fraxinus general coumarin, and that is a Fraxinus general coumarin concentrating and purifying process.
Owner:CHENGDU DIKANG PHARMA INST +1
PEGylated uricoxidase compound, preparing method, preparation and use thereof
ActiveCN101302501ALow anaphylaxisImprove uniformityPeptide/protein ingredientsSkeletal disorderSerum uric acidTumor lysis syndrome
The invention relates to a PEGylation urate oxidase compound as well as the preparation method thereof and the preparation of PEGylation urate oxidase compound as well as the application thereof, particularly relates to a PEGylation urate oxidase compound which has extremely low immunogenicity and anaphylaxis, can be applied repetitively and has a long acting as well as the preparation method thereof and the preparation of PEGylationurate oxidasee compound as well as the application thereof. The invention adopts a modification method which has high selectivity to a N-terminal of a urate oxidase, which means that PEG active ester is connected with the N-terminal of the urate oxidase by covalence bond, the uniformity of products is greatly improved, the products are easy to be purified, the activity of the purified products can be better preserved and the immunogenicity of prototype protein of the urate oxidase can be reduced obviously. The PEGylation urate oxidase compound can prevent systemic anaphylaxis when applied, can be applied repetitively and has the efficacy of treating and preventing gout, reducing the level of serum uric acid, preventing tumor lysis syndrome and improving the renal function.
Owner:刘国安 +1
Lactobacillus fermentum capable of reducing blood uric acid
ActiveCN110079476AReduce contentControl levelBacteriaSkeletal disorderMicroorganismLactobacillus fermentum
The invention relates to the field of microorganisms, and discloses lactobacillus fermentum capable of reducing blood uric acid. The strain is named 2644 strain, and is preserved at the China GeneralMicrobiological Culture Collection Center on 19th, November, 2018, and a microbial preservation number is CGMCC NO.16754; and the preservation authority address is NO.3 1# Courtyard, Beichen West Road, Chaoyang District, Beijing, and the microorganism is classified and named Lactobacillus fermentum. The strain can effectively reduce the content of the blood uric acid; and not only can intake of exogenous purines be reduced, but also discharge of internal uric acid from an intestinal tract can be promoted so that the blood uric acid level of a body can be more effectively controlled.
Owner:HANGZHOU WAHAHA TECH +1
Lactobacillus brevis DM9218 capable of reducing blood uric acid, gene segment and recombinant protein
The invention discloses lactobacillus brevis DM9218 capable of decomposing purine nucleoside with high decomposition rate at high speed and reducing blood uric acid, a gene segment and a recombinant protein. The lactobacillus brevis DM9218 (Lactobacillus brevis) is preserved in China General Microbiological Culture Collection Center with the preservation number being CGMCC NO.12797; the gene segment of the lactobacillus brevis DM9218 has a DNA (Deoxyribonucleic Acid) sequence as shown in SEQ ID NO:2; the recombinant protein of the gene segment of the lactobacillus brevis DM9218 is obtained through adopting a DNA of the lactobacillus brevis DM9218 as a template for PCR (Polymerase Chain Reaction), and utilizing a gene cloning method for a PCR product, wherein DNA sequences of an upstream primer and a downstream primer of PCR reaction are respectively as shown in SEQ ID NO:3 and SEQ ID NO:4.
Owner:DALIAN MEDICAL UNIVERSITY
Traditional Chinese medicine for treating gout
InactiveCN104352901APromote excretionEffective treatmentDispersion deliveryAnthropod material medical ingredientsSaposhnikoviaEffective treatment
The invention relates to a medicine for treating gout, in particular relates to a traditional Chinese medicine which is prepared from a plant Chinese herb and is used for treating the gout. The traditional Chinese medicine for treating the gout comprises the following components: astragalus, white peony root, coix seed, semen plantaginis, notopterygium, arisacma consanguineum, yam rhizome, angelica sinensis, rhizoma smilacis glabrae, divaricate saposhnikovia root, radix clematidis, cinnamon, nidus vespae and christina loosestrife herb. All the medicines are mixed and complete one another, so that the traditional Chinese medicine has the effects of clearing away heat and toxicity, activating blood to remove stasis, eliminating carbuncle, eliminating swelling, activating meridians to stop pain, inducing diuresis to reduce edema, tonifying spleen, dehumidifying, relaxing the muscles, eliminating numbness and the like; through the synergistic effect of the medicines, uric acid discharging in the body is promoted, and symptoms are eliminated; the action of blood uric acid is reduced, and the gout is effectively treated.
Owner:姜成玲
Traditional Chinese medicine composition for treating gouty arthritis
The invention discloses a traditional Chinese medicine composition for treating gouty arthritis. According to the traditional Chinese medicine, gouty arthritis belongs to the domain of 'arthralgia syndrome'. The disease is caused by endoretention of damp heat, detained skeleton, poor qi-blood circulation, stagnation leading to pain caused by overfeeding of greasy and surfeit flavor usually, resulting vital energy and blood retained at the local part of the scleromere, glow and swelling. Thus, the traditional Chinese medicines, namely euphorbia thymifolia, tuckahoe, yam rhizome, tonkin pepper herb, tree falsespiraea bark, siphon, delavay violet root, featherycleft horsegentian root, caulis lonicerae, herba ajugae, honeysuckle stem, herba ajugae, and rhizoma curculiginis are selected, and prepared into soup by a manufacturing laboratory in a hospital. The clinical test shows that the total effective rate achieves 96.9%; the blood uric acid is obviously reduced; the traditional Chinese medicine composition is worthy of clinical application.
Owner:广东省痛风防治医学研究院
Use of extract of non-fruit part of prune tree
ActiveCN101190280AObvious goutEfficacy of obvious goutPowder deliveryAntipyreticMedicinePlum extract
The invention discloses application of plum extract in gout. The application can be realized by decreasing blood uric acid, reducing blood fat and / or inhibiting inflammation. The invention also discloses application of plum extract in treating and preventing hyperuricemia, and the application can result in effects of treating or preventing gout.
Owner:HANGZHOU U MATE TECH +1
Saury Maillard peptide with uric acid reducing activity as well as preparation method and application thereof
ActiveCN104664039AHigh activityIncrease contentProtein composition from fishPeptide/protein ingredientsMaillard reactionHydrolysis
Owner:GUANGDONG SINOPEPTIDE BIOTECHNOLOGY CO LTD
Traditional Chinese medicine composition for treating gout
ActiveCN103933224AGood treatment effectLow costSkeletal disorderPlant ingredientsSalvia miltiorrhizaSide effect
The invention discloses a traditional Chinese medicine composition for treating gout. The traditional Chinese medicine composition for treating gout is prepared from the following raw materials in parts by weight: 8-12 parts of salvia miltiorrhiza, 6.75-12 parts of polygonum cuspidatum, 6.75-9 parts of radices sileris, 6.75-12 parts of gentiana macrophylla, 9-12 parts of scutellaria baicalensis, 4.5-8 parts of rhizoma corydalis, 4.5-8 parts of cassia twig and 6.75-12 parts of medlar. The traditional Chinese medicine composition for treating gout, which is provided by the invention, has remarkable anti-inflammatory and abirritation effects, is capable of remarkably lowering the content of blood uric acid, good in treatment effect on gout, short in treatment period, low in cost, and free from obvious toxic and side effects and adverse reactions, and provides a new choice for clinic.
Owner:周晓明
Chinese medicinal compound preparation for treating gout and hyperuricemia and preparation method thereof
InactiveCN101843814ADefinite curative effectFully enriched active ingredientsSkeletal disorderPlant ingredientsClematisBlood urate level
The invention discloses a Chinese medicinal compound preparation for treating gout and hyperuricemia and a preparation method thereof. The preparation is the Chinese medicinal compound preparation mainly prepared from the following raw materials by weight: two or more of 3 to 24g of ash bark, 3 to 24g of root of largeleaf gentian and 6 to 45g of glabrous greenbrier rhizome, and also comprises 3 to 24g of clematis root, 3 to 24g of siegesbeckia herba, 3 to 24g of atraotydin and 3 to 24g of gereanium nepalense sweet. The preparation has high active ingredient content, can effectively reduce level of blood uric acid of patients with the gout and hyperuricemia, and has exact curative effect and effective rate of 92 percent. By a macroporous resin method, the preparation has the advantages of enrichment of active ingredients of medicaments, advanced preparation process, stable and reliable quality, and multiple oral preparations.
Owner:SICHUAN DIHON MEDICAL DEV +1
Preparation and application method of PEG recombinant pig-human urate oxidase fusion protein
The invention provides a preparation method of PEG recombinant pig-human urate oxidase fusion protein, a method for preparing injecta and lyophilized injection by PEG recombinant pig-human urate oxidase fusion protein, and application for reducing content of blood uric acid. The invention further provides a nucleotide sequence of pig-human urate oxidase, which comprises vectors of nucleotide sequence and host cells containing the vectors. The PEG recombinant pig-human urate oxidase fusion protein provided with the invention has no immunogenicity substantially, maintains activity of urate oxidase before PEG and has good treatment effect for reducing the content of blood uric acid.
Owner:荆州市长新生物技术有限公司
Ring-fused compound
The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below.[in the formula,R1 is -Q1-A1 and the like; is a double bond or a single bond; when is a double bond, W1 is a nitrogen atom or a group represented by the general formula: ═C(Ra)—, and W2 is a nitrogen atom or a group represented by the general formula: ═C(Rb)—; when is a single bond, W1 is a group represented by the general formula: —C(Raa)(Rab)— or a group represented by the general formula: —(C═O)—, and W2 is a group represented by the general formula: —C(Rba)(Rbb)—, a group represented by the general formula: —(C═O)— or a group represented by the general formula: —N(Rbc)—; W3, W4 and W5 are each independently a nitrogen atom or a methine group and the like that may have a substituent; X is a single bond, an oxygen atom and the like; Y is a single bond or (CRYiRYi′)n; and Z is a hydroxyl group or COOR2 and the like.
Owner:SATO PHARMA
Food composition and pharmaceutical composition with strains of lactic acid bacteria for reducing blood uric acid concentration
InactiveUS20200214328A1Low acid concentrationBacteriaLactobacillusBiotechnologyLactic acid bacterium
A food composition and pharmaceutical composition with strains of lactic acid bacteria for reducing blood uric acid concentration are provided, comprising at least one or two isolated lactic acid bacteria strains selected from the following two: TSF331 (Lactobacillus fermentum) and TSR332 (Lactobacillus reuteri).
Owner:GLACT BIOTECH
Lactobacillus fermentum for preventing and treating hyperuricemia as well as composition and application thereof
ActiveCN113999805AGood bile salt toleranceImprove degradation rateAntibacterial agentsBacteriaBiotechnologyMetabolite
The invention discloses lactobacillus fermentum for preventing and treating hyperuricemia as well as a composition and application thereof, wherein the lactobacillus fermentum GF1800 for preventing and treating hyperuricemia has the preservation number of CCTCC NO:M 2021984. The lactobacillus fermentum GF1800 is high in biological activity and strong in acid production capacity, can effectively inhibit the activity of pathogenic microorganisms and xanthine oxidase, can tolerate gastric acid and cholate, has a remarkable degradation effect on nucleoside substances, uric acid, cholesterol, nitrite and the like, can efficiently inhibit intake of exogenous uric acid and increase of endogenous uric acid, can obviously reduce the blood uric acid level of hyperuricemia, and meanwhile, improves intestinal and kidney structural injury and inflammatory response. The invention further discloses a composition containing the lactobacillus fermentum GF1800 and a strain metabolite and postbiotics of the lactobacillus fermentum GF1800 and an application of the lactobacillus fermentum GF1800 and the postbiotics of the lactobacillus fermentum GF1800 to preparation of functional food or medicine for preventing and treating hyperuricemia or / and gout, degrading nucleoside, inhibiting xanthine oxidase, reducing cholesterol, degrading nitrite and inhibiting pathogenic bacteria.
Owner:SICHUAN GAOFUJI BIOLOGICAL TECH
Chinese medicinal formula for treating gout and hyperuricemia
ActiveCN101920002AGood treatment effectImprove efficiencySkeletal disorderPlant ingredientsMonkshoodsAnemarrhena asphodeloides
The invention relates to a Chinese medicinal formula for treating gout and hyperuricemia. The Chinese medicinal formula contains cassia twig, white paeony root, licorice root, ginger, ephedra, prepared common monkshood daughter root, large-head atractylodes rhizome, anemarrhena asphodeloides bunge, divaricate saposhnikovia root and turmeric. Pharmacological researches show that the formula can effectively reduce body blood uric acid, assist the body in dissolving and discharging urate crystal and improve kidney and arthropathology change and has good effects of diminishing inflammation and relieving pain. Related clinical experiments show that the formula for treating gout and hyperuricemia has quick response, high recovery rate and very good administration safety and nearly has no adverse reaction. The formula fills the blank that a safe and effective medicament for treating gout and hyperuricemia is not sold in the current market.
Owner:YANTAI DAYANG PHARMA GRP
Fructus gardeniae and poria cocos composite beverage and preparation method thereof
PendingCN111248382APromote excretionReduce generationSkeletal disorderNatural extract food ingredientsBiotechnologyAmomum villosum
The invention belongs to the technical field of food preparation, and particularly relates to a fructus gardeniae and poria cocos composite beverage and a preparation method thereof. The fructus gardeniae and poria cocos composite beverage is prepared from the following raw materials of fructus gardeniae, poria cocos, villous amomum fruits, chicory, mulberry leaves, corn stigma, polished glutinousrice, Chinese yams, cherries, carrots, celery, papayas, lemons, potassium citrate, sodium citrate, water and lactic acid bacteria. The fructus gardeniae and poria cocos composite beverage is suitablefor patients suffering from hyperuricaemia and gout, in multiple manners for invigorating spleen, eliminating dampness, promoting drainage of uric acid, reducing uric acid and the like, the blood uric acid level can be reduced in multiple target points, and the breaking out of the gout can be alleviated.
Owner:SHANDONG UNIV OF TECH +2
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com